Cargando…
Does β-Hydroxy-β-Methylbutyrate Have Any Potential to Support the Treatment of Duchenne Muscular Dystrophy in Humans and Animals?
Skeletal muscle is the protein reservoir of our body and an important regulator of glucose and lipid homeostasis. The dystrophin gene is the largest gene and has a key role in skeletal muscle construction and function. Mutations in the dystrophin gene cause Duchenne and Becker muscular dystrophy in...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452677/ https://www.ncbi.nlm.nih.gov/pubmed/37626825 http://dx.doi.org/10.3390/biomedicines11082329 |
_version_ | 1785095730376998912 |
---|---|
author | Gorji, Abdolvahab Ebrahimpour Ostaszewski, Piotr Urbańska, Kaja Sadkowski, Tomasz |
author_facet | Gorji, Abdolvahab Ebrahimpour Ostaszewski, Piotr Urbańska, Kaja Sadkowski, Tomasz |
author_sort | Gorji, Abdolvahab Ebrahimpour |
collection | PubMed |
description | Skeletal muscle is the protein reservoir of our body and an important regulator of glucose and lipid homeostasis. The dystrophin gene is the largest gene and has a key role in skeletal muscle construction and function. Mutations in the dystrophin gene cause Duchenne and Becker muscular dystrophy in humans, mice, dogs, and cats. Duchenne muscular dystrophy (DMD) is an X-linked neuromuscular condition causing progressive muscle weakness and premature death. β-hydroxy β-methylbutyrate (HMB) prevents deleterious muscle responses under pathological conditions, including tumor and chronic steroid therapy-related muscle losses. The use of HMB as a dietary supplement allows for increasing lean weight gain; has a positive immunostimulatory effect; is associated with decreased mortality; and attenuates sarcopenia in elderly animals and individuals. This study aimed to identify some genes, metabolic pathways, and biological processes which are common for DMD and HMB based on existing literature and then discuss the consequences of that interaction. |
format | Online Article Text |
id | pubmed-10452677 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104526772023-08-26 Does β-Hydroxy-β-Methylbutyrate Have Any Potential to Support the Treatment of Duchenne Muscular Dystrophy in Humans and Animals? Gorji, Abdolvahab Ebrahimpour Ostaszewski, Piotr Urbańska, Kaja Sadkowski, Tomasz Biomedicines Review Skeletal muscle is the protein reservoir of our body and an important regulator of glucose and lipid homeostasis. The dystrophin gene is the largest gene and has a key role in skeletal muscle construction and function. Mutations in the dystrophin gene cause Duchenne and Becker muscular dystrophy in humans, mice, dogs, and cats. Duchenne muscular dystrophy (DMD) is an X-linked neuromuscular condition causing progressive muscle weakness and premature death. β-hydroxy β-methylbutyrate (HMB) prevents deleterious muscle responses under pathological conditions, including tumor and chronic steroid therapy-related muscle losses. The use of HMB as a dietary supplement allows for increasing lean weight gain; has a positive immunostimulatory effect; is associated with decreased mortality; and attenuates sarcopenia in elderly animals and individuals. This study aimed to identify some genes, metabolic pathways, and biological processes which are common for DMD and HMB based on existing literature and then discuss the consequences of that interaction. MDPI 2023-08-21 /pmc/articles/PMC10452677/ /pubmed/37626825 http://dx.doi.org/10.3390/biomedicines11082329 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Gorji, Abdolvahab Ebrahimpour Ostaszewski, Piotr Urbańska, Kaja Sadkowski, Tomasz Does β-Hydroxy-β-Methylbutyrate Have Any Potential to Support the Treatment of Duchenne Muscular Dystrophy in Humans and Animals? |
title | Does β-Hydroxy-β-Methylbutyrate Have Any Potential to Support the Treatment of Duchenne Muscular Dystrophy in Humans and Animals? |
title_full | Does β-Hydroxy-β-Methylbutyrate Have Any Potential to Support the Treatment of Duchenne Muscular Dystrophy in Humans and Animals? |
title_fullStr | Does β-Hydroxy-β-Methylbutyrate Have Any Potential to Support the Treatment of Duchenne Muscular Dystrophy in Humans and Animals? |
title_full_unstemmed | Does β-Hydroxy-β-Methylbutyrate Have Any Potential to Support the Treatment of Duchenne Muscular Dystrophy in Humans and Animals? |
title_short | Does β-Hydroxy-β-Methylbutyrate Have Any Potential to Support the Treatment of Duchenne Muscular Dystrophy in Humans and Animals? |
title_sort | does β-hydroxy-β-methylbutyrate have any potential to support the treatment of duchenne muscular dystrophy in humans and animals? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452677/ https://www.ncbi.nlm.nih.gov/pubmed/37626825 http://dx.doi.org/10.3390/biomedicines11082329 |
work_keys_str_mv | AT gorjiabdolvahabebrahimpour doesbhydroxybmethylbutyratehaveanypotentialtosupportthetreatmentofduchennemusculardystrophyinhumansandanimals AT ostaszewskipiotr doesbhydroxybmethylbutyratehaveanypotentialtosupportthetreatmentofduchennemusculardystrophyinhumansandanimals AT urbanskakaja doesbhydroxybmethylbutyratehaveanypotentialtosupportthetreatmentofduchennemusculardystrophyinhumansandanimals AT sadkowskitomasz doesbhydroxybmethylbutyratehaveanypotentialtosupportthetreatmentofduchennemusculardystrophyinhumansandanimals |